StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
348
This month
7
This year
7
Publishing Date
2022 - 12 - 09
4
2022 - 09 - 13
3
2022 - 08 - 15
3
2022 - 08 - 04
2
2022 - 08 - 02
2
2022 - 07 - 12
2
2022 - 07 - 04
2
2022 - 06 - 03
3
2022 - 05 - 24
2
2022 - 04 - 20
2
2022 - 04 - 19
2
2022 - 04 - 13
2
2022 - 03 - 28
2
2022 - 02 - 28
2
2022 - 02 - 24
2
2022 - 02 - 10
2
2022 - 02 - 01
2
2022 - 01 - 18
2
2022 - 01 - 14
2
2022 - 01 - 10
3
2021 - 12 - 21
2
2021 - 11 - 29
4
2021 - 11 - 19
2
2021 - 11 - 15
2
2021 - 11 - 11
2
2021 - 10 - 28
2
2021 - 10 - 21
2
2021 - 10 - 14
2
2021 - 10 - 07
2
2021 - 09 - 20
3
2021 - 09 - 16
3
2021 - 08 - 19
2
2021 - 08 - 12
3
2021 - 08 - 10
2
2021 - 08 - 05
3
2021 - 08 - 04
2
2021 - 07 - 29
2
2021 - 07 - 12
2
2021 - 06 - 25
2
2021 - 06 - 24
4
2021 - 06 - 23
2
2021 - 06 - 22
2
2021 - 06 - 21
3
2021 - 06 - 17
2
2021 - 06 - 10
2
2021 - 06 - 09
2
2021 - 06 - 04
5
2021 - 05 - 20
3
2021 - 05 - 06
2
2021 - 04 - 15
2
2021 - 04 - 14
2
2021 - 04 - 13
2
2021 - 03 - 22
2
2021 - 03 - 19
2
2021 - 03 - 18
2
2021 - 03 - 15
2
2021 - 03 - 11
3
2021 - 03 - 09
2
2021 - 03 - 04
2
2021 - 01 - 11
2
Sector
Commercial services
1
Communications
2
Distribution services
1
Electronic technology
2
Energy minerals
1
Finance
7
Finance and insurance
1
Health services
4
Health technology
348
Manufacturing
15
N/a
4
Process industries
4
Professional, scientific, and technical services
2
Retail trade
1
Technology services
1
Tags
Alliances
18
Antiviral
8
Application
9
Approval
15
Bioscience
10
Biotech
7
Biotech-bay
30
Biotech-beach
7
Biotechnology
6
Breast cancer
22
Cancer
47
Ces
7
China
8
Chmp
8
Clinical-trials-phase-iii
9
Collaboration
18
Conference
13
Covid
14
Covid-19
12
Disease
17
Drug
23
Earnings
11
Europe
7
Events
13
Fda
16
Fda-approvals
7
Financial results
20
For
26
Genetown
7
Global
16
Health
8
Hepatitis
10
Hiv
23
Iot
8
Leukemia
7
License
9
Liver
7
Market
23
N/a
154
People
19
Pharma
8
Phase 2
8
Phase 3
9
Positive
9
Potential
7
Pre-clinical
9
Preclinical
9
Regulatory
7
Report
12
Research
38
Results
31
Sciences
14
T-cell
20
Technology
9
Therapeutics
31
Therapy
39
Treatment
38
Trial
16
Trodelvy
10
Yescarta
7
Entities
3m company
634
Abb ltd
870
Abbott laboratories
1020
Abbvie inc.
636
Accenture plc
351
Alphabet inc.
520
Amgen inc.
476
Apple inc.
687
Arcelormittal
343
Arrival
2407
Astrazeneca plc
407
Becton, dickinson and company
555
Bnp paribas
971
Boston scientific corporation
394
Bristol-myers squibb company
443
Cisco systems, inc.
598
Danaher corporation
483
Dow inc.
373
Duke energy corporation
329
Eli lilly and company
1127
Ericsson
1022
Extreme networks, inc.
478
First bank
397
Firstenergy corp.
344
Ford motor company
379
Gartner, inc.
334
General electric company
646
Gilead sciences, inc.
348
Glaxosmithkline plc
598
Honeywell international inc.
1073
Hubspot, inc.
1010
Intel corporation
617
International business machines corporation
418
Johnson & johnson
2875
Kering
594
Koninklijke philips n.v.
613
Lithium corp
528
Live nation entertainment, inc.
459
Lockheed martin corporation
374
Medtronic plc
868
Microsoft corporation
835
Morgan stanley
2595
Nokia corp
460
Nokia corporation
477
Northrop grumman corporation
382
Novartis ag
728
Novo nordisk a/s
398
Ooma, inc.
390
Oracle corporation
774
Orange
3460
Panasonic corp
395
Pfizer, inc.
502
Sanofi
2651
Sap se
922
Snowflake inc.
517
Teva pharmaceutical industries ltd
359
Thermo fisher scientific inc
929
Total se
981
Verizon communications inc.
639
X financial
360
Symbols
AADI
3
ABBV
25
ABEO
2
ABT
9
ACLX
2
ADAP
3
ADXS
2
ADXSD
2
AGTC
2
ALNY
5
ALVR
3
ALXN
6
AMGN
29
ARPO
2
ASMB
3
AZN
8
AZNCF
6
BCRX
13
BLUE
4
BMRN
4
BMY
34
BNTX
3
CRSP
3
EDIT
3
GILD
348
GLAXF
13
GLPG
10
GLPGF
6
GMAB
3
GSK
17
HGEN
3
HOOK
12
JNCE
24
JNJ
28
LLY
28
MRK
5
MYL
3
NEOS
13
NRXP
3
NTLA
3
NVO
8
NVS
19
NVSEF
16
OMER
13
OTIC
13
PFE
25
REGN
10
SGMO
3
SNY
51
SNYNF
22
SRNE
3
SRPT
3
SUPN
3
TAK
10
TARA
3
TEVJF
4
TMO
3
VERU
4
VIR
3
XERS
11
Exchanges
Amex
2
Lse
6
Nasdaq
348
Nyse
83
Tsx
2
Crawled Date
2022 - 12 - 09
4
2022 - 09 - 13
3
2022 - 08 - 09
2
2022 - 08 - 04
2
2022 - 08 - 02
2
2022 - 07 - 12
2
2022 - 07 - 04
2
2022 - 06 - 03
3
2022 - 04 - 20
2
2022 - 04 - 19
2
2022 - 04 - 13
2
2022 - 03 - 31
2
2022 - 03 - 28
2
2022 - 02 - 28
2
2022 - 02 - 10
2
2022 - 02 - 01
2
2022 - 01 - 19
2
2022 - 01 - 14
2
2022 - 01 - 10
3
2021 - 12 - 21
2
2021 - 12 - 15
2
2021 - 11 - 29
4
2021 - 11 - 19
2
2021 - 11 - 15
2
2021 - 11 - 11
2
2021 - 10 - 28
2
2021 - 10 - 21
2
2021 - 10 - 14
2
2021 - 10 - 07
2
2021 - 09 - 20
3
2021 - 09 - 16
3
2021 - 08 - 19
2
2021 - 08 - 12
3
2021 - 08 - 10
2
2021 - 08 - 05
3
2021 - 08 - 04
2
2021 - 07 - 29
2
2021 - 07 - 12
2
2021 - 06 - 25
2
2021 - 06 - 24
4
2021 - 06 - 23
2
2021 - 06 - 22
3
2021 - 06 - 21
2
2021 - 06 - 17
2
2021 - 06 - 10
2
2021 - 06 - 09
2
2021 - 06 - 04
5
2021 - 05 - 20
3
2021 - 05 - 06
2
2021 - 04 - 15
2
2021 - 04 - 14
2
2021 - 04 - 13
3
2021 - 03 - 22
2
2021 - 03 - 19
2
2021 - 03 - 18
2
2021 - 03 - 15
2
2021 - 03 - 11
4
2021 - 03 - 09
2
2021 - 03 - 04
2
2021 - 01 - 11
2
Crawled Time
00:00
9
00:20
1
01:00
14
02:00
1
03:00
1
04:00
3
06:00
3
07:00
5
08:00
3
09:00
3
09:52
1
10:00
3
10:51
1
11:00
19
11:33
3
12:00
37
12:03
1
12:06
1
12:15
12
12:20
6
12:30
1
12:34
1
13:00
37
13:01
1
13:07
1
13:15
5
13:17
1
13:20
14
13:27
1
13:30
1
13:52
1
14:00
24
14:01
1
14:03
2
14:15
3
14:20
6
14:30
5
15:00
15
15:15
2
15:17
1
15:20
2
15:30
1
15:49
1
15:56
1
15:59
1
16:00
11
16:20
2
17:00
9
17:43
1
18:00
6
18:11
1
18:32
1
19:00
7
19:47
1
20:00
9
21:00
11
21:03
1
22:00
20
23:00
12
Source
galmedpharma.com
1
investor.assemblybio.com
1
ir.voyagertherapeutics.com
1
www.biospace.com
193
www.fda.gov
19
www.globenewswire.com
53
www.igmbio.com
1
www.prnewswire.com
79
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
entities :
Gilead sciences, inc.
save search
SK bioscience Appoints New Executives to Accelerate New Growth Strategies
Published:
2023-01-20
(Crawled : 12:20)
- prnewswire.com
SNY
|
News
|
$48.49
-0.66%
-0.66%
1.1M
|
Health Technology
|
-1.6%
|
O:
-0.41%
H:
0.0%
C:
0.0%
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-0.57%
|
O:
-0.7%
H:
0.0%
C:
0.0%
BMRN
M
|
$117.27
0.25%
0.25%
1.2M
|
Health Technology
|
6.09%
|
O:
-0.59%
H:
0.0%
C:
0.0%
bioscience
growth
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
Published:
2023-01-19
(Crawled : 23:00)
- biospace.com/
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-0.14%
|
O:
0.43%
H:
0.0%
C:
0.0%
sciences
year
financial
results
Global Prescription Drugs Market Analysis Report 2022: Increasing Number of Chronic Diseases Worldwide will Continue to Fuel Growth - Forecast to 2027
Published:
2023-01-19
(Crawled : 17:00)
- prnewswire.com
TAK
|
News
|
$16.03
-0.43%
0.0%
3.7M
|
Health Technology
|
-0.68%
|
O:
0.03%
H:
0.0%
C:
0.0%
NVO
|
$138.09
0.4%
1.38%
1.1M
|
Health Technology
|
-1.59%
|
O:
0.14%
H:
0.0%
C:
0.0%
NVS
|
News
4 d
|
$89.49
-0.39%
0.01%
1.7M
|
Health Technology
|
-2.98%
|
O:
0.0%
H:
0.0%
C:
0.0%
JNJ
|
News
3 d
|
$168.23
-0.39%
-0.04%
6M
|
Health Technology
|
-1.86%
|
O:
-1.45%
H:
0.0%
C:
0.0%
GSK
|
News
|
$35.3
-0.11%
0.14%
3.5M
|
Health Technology
|
0.37%
|
O:
0.23%
H:
0.0%
C:
0.0%
LLY
|
News
|
$342.1
-1.7%
0.12%
2.3M
|
Health Technology
|
-3.14%
|
O:
-1.35%
H:
0.0%
C:
0.0%
BMY
|
News
|
$72.45
-0.74%
0.0%
5.4M
|
Health Technology
|
1.05%
|
O:
0.19%
H:
0.0%
C:
0.0%
ABBV
|
News
|
$146.28
-0.76%
0.06%
4.6M
|
Health Technology
|
-3.18%
|
O:
-2.16%
H:
0.0%
C:
0.0%
SNY
|
News
|
$48.49
-0.66%
-0.66%
1.1M
|
Health Technology
|
-2.51%
|
O:
-0.92%
H:
0.0%
C:
0.0%
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-0.14%
|
O:
0.43%
H:
0.0%
C:
0.0%
AMGN
|
News
|
$253.68
-0.47%
-0.47%
2.1M
|
Health Technology
|
-3.58%
|
O:
-0.9%
H:
0.0%
C:
0.0%
global
report
growth
market
Strata Oncology Announces Addition of Gilead as Strata PATH Trial Collaborator
Published:
2023-01-18
(Crawled : 14:20)
- prnewswire.com
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-2.1%
|
O:
-0.46%
H:
0.12%
C:
-1.51%
trial
Tune Therapeutics Welcomes Noted Industry Leader Dr. John McHutchison to Board of Directors
Published:
2023-01-17
(Crawled : 14:20)
- biospace.com/
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-2.14%
|
O:
0.7%
H:
0.37%
C:
-0.74%
ASMB
|
$1.7
1.19%
1.18%
370K
|
Health Technology
|
13.13%
|
O:
7.07%
H:
1.26%
C:
-1.26%
therapeutics
Global Antiviral Therapeutics Market 2022 to 2027 - Rising Prevalence of Viral Diseases like HIV and Hepatitis Drives Growth
Published:
2023-01-16
(Crawled : 20:00)
- prnewswire.com
PFE
|
$43.79
-1.04%
0.0%
23M
|
Health Technology
|
-7.56%
|
O:
-2.74%
H:
0.0%
C:
0.0%
JNJ
|
News
3 d
|
$168.23
-0.39%
-0.04%
6M
|
Health Technology
|
-2.81%
|
O:
0.51%
H:
0.0%
C:
0.0%
BMY
|
News
|
$72.45
-0.74%
0.0%
5.4M
|
Health Technology
|
1.65%
|
O:
1.94%
H:
0.52%
C:
-1.09%
ABT
|
News
|
$109.95
-1.01%
0.0%
4.9M
|
Health Technology
|
-0.56%
|
O:
2.05%
H:
0.69%
C:
-0.1%
SNY
|
News
|
$48.49
-0.66%
-0.66%
1.1M
|
Health Technology
|
-1.56%
|
O:
1.1%
H:
0.22%
C:
0.02%
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-2.14%
|
O:
0.7%
H:
0.37%
C:
-0.74%
hepatitis
global
antiviral
hiv
therapeutics
growth
market
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
Published:
2023-01-03
(Crawled : 15:00)
- biospace.com/
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-1.81%
|
O:
-0.01%
H:
0.0%
C:
0.0%
collaboration
therapeutics
Global Precision Cancer Therapeutics Market Report 2022: Overview of Disease Epidemiology, Leading Product sales, Market Estimates and Forecasts, and Competitive Summary of Leading Providers
Published:
2022-12-30
(Crawled : 15:00)
- prnewswire.com
PFE
|
$43.79
-1.04%
0.0%
23M
|
Health Technology
|
-13.95%
|
O:
0.02%
H:
0.0%
C:
0.0%
NVS
|
News
4 d
|
$89.49
-0.39%
0.01%
1.7M
|
Health Technology
|
-2.39%
|
O:
-0.03%
H:
0.0%
C:
0.0%
JNJ
|
News
3 d
|
$168.23
-0.39%
-0.04%
6M
|
Health Technology
|
-5.05%
|
O:
-0.01%
H:
0.0%
C:
0.0%
BMY
|
News
|
$72.45
-0.74%
0.0%
5.4M
|
Health Technology
|
1.11%
|
O:
0.13%
H:
0.0%
C:
0.0%
SNY
|
News
|
$48.49
-0.66%
-0.66%
1.1M
|
Health Technology
|
-0.08%
|
O:
-0.39%
H:
0.0%
C:
0.0%
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-1.92%
|
O:
-0.12%
H:
0.0%
C:
0.0%
EXEL
M
|
$17.48
-1.3%
-1.32%
1.6M
|
Health Technology
|
13.09%
|
O:
0.03%
H:
0.0%
C:
0.0%
AZN
|
$65.54
-0.68%
-0.69%
3.1M
|
Health Technology
|
-3.1%
|
O:
-0.5%
H:
0.0%
C:
0.0%
global
disease
report
therapeutics
cancer
market
Hagens Berman Sobol Shapiro LLP, Hilliard & Shadowen LLP, and Durie Tangri LLP Announce a Class Action Involving Antiretroviral Drugs
Published:
2022-12-28
(Crawled : 21:00)
- prnewswire.com
JNJ
|
News
3 d
|
$168.23
-0.39%
-0.04%
6M
|
Health Technology
|
-5.29%
|
O:
-0.26%
H:
0.42%
C:
0.01%
BMY
|
News
|
$72.45
-0.74%
0.0%
5.4M
|
Health Technology
|
0.16%
|
O:
-0.66%
H:
0.47%
C:
-0.28%
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-2.29%
|
O:
-0.78%
H:
0.78%
C:
0.41%
Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics
Published:
2022-12-27
(Crawled : 22:00)
- globenewswire.com
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-1.95%
|
O:
0.35%
H:
0.0%
C:
0.0%
gs-1811
immunotherapy
potential
HIV Clinical Trials Market Research Report by Phase, Study Design, Sponsor, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published:
2022-12-26
(Crawled : 13:20)
- prnewswire.com
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
Email alert
Add to watchlist
NVO
|
$138.09
0.4%
1.38%
1.1M
|
Health Technology
|
Email alert
Add to watchlist
PFE
|
$43.79
-1.04%
0.0%
23M
|
Health Technology
|
Email alert
Add to watchlist
SYNH
|
$36.09
-0.22%
-0.22%
870K
|
Health Services
|
Email alert
Add to watchlist
ICLR
|
$228.26
-1.21%
-1.22%
370K
|
Health Technology
|
Email alert
Add to watchlist
LLY
|
News
|
$342.1
-1.7%
0.12%
2.3M
|
Health Technology
|
Email alert
Add to watchlist
covid-19
trials
research
global
report
hiv
impact
study
market
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
Published:
2022-12-22
(Crawled : 18:00)
- biospace.com/
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-1.94%
|
O:
-0.2%
H:
0.0%
C:
0.0%
sunlenca
treatment
fda
for
hiv
approval
living
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
Published:
2022-12-20
(Crawled : 13:20)
- biospace.com/
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-2.86%
|
O:
-2.84%
H:
1.93%
C:
1.35%
acquire
t-cell
therapeutics
therapy
cancer
Voyager Therapeutics Appoints Grace E. Colón, Ph.D., to its Board of Directors
Published:
2022-12-14
(Crawled : 12:00)
- ir.voyagertherapeutics.com
VYGR
S
|
$9.005
0.17%
0.17%
250K
|
Health Technology
|
40.69%
|
O:
-2.35%
H:
1.76%
C:
-6.41%
PGEN
|
News
0 d
|
$1.64
1.23%
1.22%
4.3M
|
Health Technology
|
-0.9%
|
O:
0.9%
H:
2.98%
C:
1.79%
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-6.61%
|
O:
-1.7%
H:
0.0%
C:
0.0%
CDNA
F
|
$15.28
0.53%
0.52%
440K
|
Health Technology
|
13.52%
|
O:
-5.83%
H:
4.12%
C:
1.9%
therapeutics
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
Published:
2022-12-12
(Crawled : 19:00)
- biospace.com/
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-6.09%
|
O:
-1.34%
H:
0.81%
C:
0.79%
yescarta
ongoing
lymphomas
t-cell
therapy
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
Published:
2022-12-09
(Crawled : 16:00)
- biospace.com/
ACLX
|
$34.0
2.6%
2.53%
370K
|
|
65.99%
|
O:
30.25%
H:
0.0%
C:
0.0%
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-4.53%
|
O:
1.66%
H:
0.0%
C:
0.0%
collaboration
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
Published:
2022-12-09
(Crawled : 14:00)
- biospace.com/
ACLX
|
$34.0
2.6%
2.53%
370K
|
|
65.99%
|
O:
30.25%
H:
0.0%
C:
0.0%
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-4.53%
|
O:
1.66%
H:
0.0%
C:
0.0%
collaboration
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
Published:
2022-12-09
(Crawled : 13:00)
- biospace.com/
IMGN
|
$4.745
0.74%
0.74%
1.7M
|
Health Technology
|
-8.37%
|
O:
-0.39%
H:
0.0%
C:
0.0%
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-4.53%
|
O:
1.66%
H:
0.0%
C:
0.0%
collaboration
leukemia
acute myeloid leukemia
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model Myriad Genetics, Inc., a leader in genetic testing and preci...
Published:
2022-12-09
(Crawled : 13:00)
- biospace.com/
SXT
|
$72.54
-0.82%
0.0%
75K
|
Distribution Services
|
0.01%
|
O:
1.04%
H:
0.0%
C:
0.0%
PFE
|
$43.79
-1.04%
0.0%
23M
|
Health Technology
|
-11.94%
|
O:
3.66%
H:
0.0%
C:
0.0%
TRIB
|
$1.085
-5.65%
-5.99%
47K
|
Health Technology
|
-10.16%
|
O:
-7.03%
H:
0.0%
C:
0.0%
REPL
|
$25.89
-0.92%
-0.93%
350K
|
Health Technology
|
15.01%
|
O:
5.04%
H:
0.0%
C:
0.0%
MYGN
|
$20.38
2.88%
2.8%
320K
|
Health Technology
|
1.33%
|
O:
0.15%
H:
0.0%
C:
0.0%
IMGN
|
$4.745
0.74%
0.74%
1.7M
|
Health Technology
|
-8.37%
|
O:
-0.39%
H:
0.0%
C:
0.0%
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-4.53%
|
O:
1.66%
H:
0.0%
C:
0.0%
BNTX
|
$143.69
0.81%
0.8%
440K
|
Health Technology
|
-12.6%
|
O:
4.9%
H:
0.0%
C:
0.0%
risk
breast
genetic
cancer
study
Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress
Published:
2022-12-08
(Crawled : 13:00)
- globenewswire.com
JNCE
|
$1.19
5.31%
5.04%
510K
|
Health Technology
|
46.01%
|
O:
1.82%
H:
1.52%
C:
-7.91%
GILD
F
|
$83.7
0.1%
0.1%
4.1M
|
Health Technology
|
-5.02%
|
O:
-0.51%
H:
0.0%
C:
0.0%
medical
trial
therapeutics
← Previous
1
2
3
4
5
6
7
8
9
…
17
18
Next →
Gainers vs Losers
66%
34%
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.